Revenue segments as reported by the company.

Immunology

Hematologic Oncology

Aesthetics

Neuroscience

Eye Care

Women's Health

Other Key Products

All other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Acquired in-process research and development

Other operating expense

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

AbbVie

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

AbbVie surpasses Q4 earnings forecast, eyes growth amid challenges

AbbVie's strong performance in Q4 2022 exceeded expectations, driven by key products like SKYRIZI and RINVOQ. Despite challenges in revenue and HUMIRA erosion, the company is focused on innovation and growth opportunities. Strategic investments in R&D and BD aim to navigate market dynamics and drive future success.

AbbVie surpasses Q1 expectations, eyes international growth amid challenges

AbbVie's Q1 2023 performance exceeded expectations, driven by key product sales and strong international results. While facing challenges in the U.S. market and inflationary pressures, the company remains confident in its long-term growth prospects and strategic initiatives.

AbbVie surpasses Q2 expectations, eyes revenue growth opportunities

AbbVie's Q2 2023 earnings call highlighted strong financial performance, successful execution in key therapeutic areas, and a promising outlook for revenue growth. Despite challenges like biosimilar competition and market dynamics, the company remains confident in its ability to deliver value and maintain growth.

AbbVie exceeds Q3 expectations, focuses on pipeline growth strategies

AbbVie's strong Q3 performance driven by key products and growth platforms, with positive trial results.
Challenges in aesthetics sales and Medicare drug pricing program offset by long-term growth opportunities.
Confidence in pipeline assets and strategic focus on combination therapies for future growth.
Maintaining strong market positions and investing in transformative therapies for competitive advantage.

AbbVie exceeds Q4 expectations, eyes growth through strategic acquisitions

AbbVie's stellar performance in Q4 2023 showcased strong sales growth, successful pipeline advancements, and strategic acquisitions. While facing challenges such as pricing pressures and safety concerns, the company is well-positioned to capitalize on opportunities in expanding its portfolio and driving growth through innovation and strategic partnerships.

AbbVie exceeds Q1 expectations, raises full-year guidance on strong sales growth

AbbVie's Q1 performance exceeded expectations, with strong sales growth in key products. The company raised full-year guidance and remains confident in maintaining good access for its brands. Challenges in aesthetics sales and inventory management are being addressed for future growth.

AbbVie reports robust Q2 results and raises 2024 guidance

AbbVie's strong Q2 performance, raised guidance, and strategic acquisitions highlight its growth trajectory.
Despite near-term challenges, the company's focus on key growth areas positions it for long-term success.
Investments in innovation and market expansion underscore AbbVie's commitment to sustained growth.
Overall, AbbVie's performance in Q2 2024 reflects a resilient and forward-looking approach to business.

AbbVie reports strong Q3 performance, raises guidance and dividend

AbbVie's Q3 2024 performance showcased robust sales growth, increased dividend, and raised revenue guidance, reflecting financial strength and market leadership.
The company's focus on long-term sustainability through investments, acquisitions, and pipeline advancements highlights a commitment to innovation and growth.
While facing challenges in clinical trial management and market competition, AbbVie remains well-positioned to leverage opportunities in diverse therapeutic areas for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Apple

Caesars Entertainment

Etsy

Alphabet

Gap Inc

eBay

Finding the right combination of growth and value is like the holy grail of investing. Let's look at 7 S&P 500 stocks that fit the bill.

7 S&P 500 Stocks to Buy for Growth and Value

NORTH CHICAGO, Ill., Aug. 24, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the European Commission (EC) approved RINVOQ® (upadacitinib), an oral, selective and reversible JAK inhibitor, for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy.1 The recommended dose of RINVOQ for atopic dermatitis in adults is 15 mg or 30 mg once daily based on individual patient presentation, and 15 mg once daily for adolescents (12-17 years of age) and adults 65 years and older.1 RINVOQ can be used with or without topical corticosteroids (TCS).1 "This is a significant milestone for AbbVie in our pursuit to transform care in atopic dermatitis," said Michael Severino, M.D.

European Commission Approves RINVOQ® (upadacitinib) as First JAK Inhibitor in the European Union for the Treatment of Both Adults and Adolescents with Moderate to Severe Atopic Dermatitis

Roche Holding AG

Roche Holding AG ( RHHBY , Financial) sits atop the list of pharmaceutical companies that are getting the most out of research and development spending. That's an important consideration for investors given new products with blockbuster potential are the lifeblood of the industry.

Roche, AbbVie Top R&D Productivity in Past 5 Years

Johnson & Johnson

Pfizer

These pharmaceutical giants offer strong, dependable dividends and the size to weather the market's ups and downs.

3 Boring Healthcare Stocks Everyone Should Own

The S&P 500 continues to trend higher and set record highs, even though we've had a few down days recently. Despite the record highs, I will always continue to search for undervalued dividend stocks to buy.

AbbVie: A Dividend Stock To Buy? - Dividend Stock Analysis

Albemarle

Franklin Resources

Ecolab

Essex Property Trust

Federal Realty Investment Trust

Altria

ProShares S&P 500 Dividend Aristocrats ETF

AT&T

West Pharmaceutical Services

Exxon Mobil

Dividend Aristocrats can be great investments, as they combine resilience, above-average yields, and income growth.

Dividend Aristocrats: 5 To Buy And 5 To Avoid

Anthem

Cisco Systems

Chevron

Home Depot

Lowe's

Microsoft

T. Rowe Price Group

Texas Instruments

Wells Fargo

Xcel Energy

This is a quarterly review of DivGro, my portfolio of dividend growth stocks. I write these reviews to summarize investment decisions and to share portfolio statistics. The article includes charts showing DivGro's composition and how positions contribute to projected annual dividend income.

Quarterly Review Of DivGro: Q2-2021

My last article analyzed AbbVie Inc. (ABBV) under the framework of perpetual growth and Buffett's 10x Pretax Rule.

AbbVie Inc.: Bull Thesis Strengthened By Marginal ROCE Results

NORTH CHICAGO, Ill., Aug. 18, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the New England Journal of Medicine (NEJM) has published 12-week results from the Phase 3 ADVANCE trial evaluating atogepant for the preventive treatment of migraine in adults who meet criteria for episodic migraine.

New England Journal of Medicine Publishes 12-Week Results from Study Evaluating Atogepant for the Preventive Treatment of Migraine

Edison

Coca-Cola

Simple, straightforward, recurring revenue kinds of products make these names perfect dividend-paying companies.

Like Dividends? I Bet You'll Love These 3 Stocks

Biogen

Bristol-Myers

General Motors

Kroger

Merck

Buffett stocks are a hot topic among investors as they look to go long on some fresh plays. Kroger and Aon are among Berkshire's favorites.

7 Buffett Stocks to Buy (and Sell) if You Want to Be Like Berkshire

AstraZeneca

Virtus Investment Partners

Each of these companies makes for a great vehicle to play an aging demographic.

3 Top Biotech Stocks to Buy in August

Warren Buffett-led Berkshire Hathaway Inc (NYSE: BRK-A) (NYSE: BRK-B) sharply lowered its exposure in General Motors Co (NYSE: GM), Merck & Co Inc (NYSE: MRK), AbbVie Inc (NYSE: ABBV), Bristol-Myers Squibb Co (NYSE: BMY) and added positions in Kroger Inc (NYSE: KR) and Aon Plc (NYSE: AON), in the second quarter, regulatory filings revealed on Monday. What Happened: The Omaha, Nebraska-based conglomerate disclosed it has trimmed its position in the legacy automaker GM by 10.44%, as it shed 60 million shares, lowering its total stake in GM to $3.55 billion at the end of June, compared with $3.85 billion a quarter ago.

Apple, GM, Kroger, AbbVie, Merck, Bristol Myers Squibb, Biogen — How Warren Buffett's Berkshire Adjusted Its Portfolio In Q2

Axalta Coating Systems

Liberty Global Ltd

Marsh & McLennan

Organon & Co

U.S. Bancorp

Berkshire Hathaway CEO Warren Buffett and his team were bears yet again in Q2 2021, hacking away at a large number of positions while only adding to a handful.

11 Stocks Warren Buffett Is Selling (And 3 He's Buying)

Warren Buffett's Berkshire Hathaway Inc said on Monday it trimmed or eliminated its stakes in several pharmaceutical companies, and reported a small new stake in a Merck & Co spinoff, Organon & Co.

Buffett's Berkshire pares drug holdings, sheds Axalta, Biogen

Allstate

Best Buy

Goldman Sachs

Huntington Ingalls Industries

L3Harris

Medifast

Morgan Stanley

SPDR S&P 500 ETF Trust

This monthly series ranks a selection of dividend growth stocks in Dividend Radar and presents the ten top-ranked stocks for consideration.

10 Dividend Growth Stocks For August 2021

If the drug can overcome JAK inhibitor-class concerns, it could capture share in the growing atopic dermatitis market.

What Rinvoq's Positive News Means for AbbVie

The company's future looks increasingly bright.

3 Key Takeaways From AbbVie's Second-Quarter Earnings

AbbVie management has set itself the tough challenge of dealing with the patent expiry of $20bn selling Humira while maintaining top-line revenue growth.

AbbVie: Strong Earnings Make Bull Case For Reassuringly Undervalued Pharma

AbbVie Inc (NYSE: ABBV) has advanced its collaboration with privately-held Mission Therapeutics, with the nomination of two DUB targets to take into the next stage of drug discovery. This selection follows supportive data from in vitro and in vivo Alzheimer's and Parkinson's disease models.

AbbVie, Mission Therapeutics Pick Alzheimer's & Parkinson's Targets In Neurodegenerative Disease Collaboration

News for AbbVie Stock (ABBV)